Company / Cash & Equivalents
STAAR Surgical Company Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$153.2M
FY2025
5-year range
$86.5M / $199.7M
FY2021-FY2025
Trend
+6.2%
vs FY2024
Sector context
#96 of 148
Health Care
What the data says
At $153M, STAAR Surgical Company's cash & equivalents ranks #96 of 148 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $14M in FY2017 to $200M in FY2021.
Based on SEC 10-K filings.
$153M in FY2025 with a 5-year CAGR of +0.1%.
Declined from $183M to $153M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +21.0%
- 5-Year CAGR
- +0.1%
- 10-Year CAGR
- -
Sector benchmark
#96 of 148 in Health CareTop 65% of 148This company $153.2M Sector average $1.2B
▼
-87.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.1%, indicating consistent growth.
- In FY2025, cash & equivalents increased 6.2% year-over-year.
- Ranks #96 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Negative profit margin: -6.4%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $153.2M | +6.2% |
| FY2024 | $144.2M | -21.2% |
| FY2023 | $183.0M | +111.7% |
| FY2022 | $86.5M | -56.7% |
| FY2021 | $199.7M | +31.0% |
| FY2020 | $152.5M | +27.1% |
| FY2019 | $120.0M | +547.8% |
| FY2018 | $18.5M | +32.3% |
| FY2017 | $14.0M | +0.0% |
| FY2016 | $14.0M | +4.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026